About BigHat
BigHat is a Healthcare company based in San Carlos (United States) founded in 2019 by Peyton Greenside and Mark DePristo. It operates as an antibody therapies are developed through machine learning and synthetic biology. BigHat has raised $223.41 million across 4 funding rounds from investors including Bristol-Myers Squibb, Amgen Business Development and Quadrille Capital. BigHat has completed 1 acquisition, including BigHat Biosciences. Its chief executive is Mark DePristo. BigHat offers products and services including Milliner Platform. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include argenx, MacroGenics, Owkin, Formation Bio and Alexion and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
BigHat was founded in 2019 and is based in San Carlos, United States. Antibody therapies are provided by the company using machine learning and synthetic biology. An AI-enabled platform called Milliner is offered to design antibodies targeting intractable conditions, including chronic illnesses and life-threatening diseases. Operations focus on the biotechnology sector, with services aimed at therapeutic development for complex health challenges.
- Headquarters San Carlos, United States
- Founders Peyton Greenside, Mark DePristo
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website bighatbio.com
- Social LinkedIn X
- Total Equity Funding$223.41M (USD)
in 4 rounds
- Latest Funding Round$75M (USD), Series C
Sep 2026
- InvestorsBristol-Myers Squibb
& 20 more
- Investments & Acquisitions
Products & Services of BigHat
BigHat offers a comprehensive portfolio of products and services, including Milliner Platform.
Integrates machine learning and wet lab for faster antibody engineering and design
Funding Insights of BigHat
BigHat has successfully raised a total of $223.41M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $75 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $223.41M
- Total Rounds 4
- Last Round Series C — $75M
- First Round $5.3M
(Dec 2019)
- Investors Count 21
All 4 funding rounds of BigHat with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $75M | Series C | – | DFJ Growth, Premji Invest | |
| Jun 2022 | $124.11M | Series B | – | S32 | |
| Feb 2021 | $19M | Series A | – | a16z | |
| Dec 2019 | $5.3M | Series A | – | – | – |
21 investors in total: 21 institutional.
Investors in BigHat
BigHat has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Amgen Business Development and Quadrille Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are facilitated by Amgen-backed entity. | – | amgenbd.com | Thousand Oaks, United States | |
Sector-agnostic investment company making venture capital investments globally | – | quadrillecapital.com | Paris, France | |
Venture capital investing with a focus on diversity and inclusion in the ecosystem. | – | gaingels.com | - | |
AI, robotics, life science, nanotechnology sectors are invested in | – | gridscapital.com | Sao Paulo, Brazil | |
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | – | a16z.com | - | |
AME Cloud Ventures is focused on investing in data-driven technology companies. | – | amecloudventures.com | Palo Alto, United States | |
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Tech startups are funded by S32, a venture capital entity. | – | s32.com | Sunnyvale, United States | |
Early-stage technology investments are targeted by this venture capital firm. | – | innovationendeavors.com | Palo Alto, United States | |
- | – | dfjgrowth.com | - |
Investor details for BigHat
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BigHat
51 people are tracked at BigHat (11 in leadership, 17 in board & advisors, 23 in team).
| Name | Role | Group |
|---|---|---|
Peyton Greenside | Co-Founder & CSO | Leadership |
Mark DePristo | Co-Founder & CEO | Leadership |
John Corbin | Chief Development Officer | Leadership |
Jordan Sullivan | Associate Director, Production & Reagents | Leadership |
Ryan Henrici M.D. | Vice President, Discovery Medicine | Leadership |
Anthony Cadena | Associate Director, Discovery Medicine | Leadership |
Sangeetha Iyer | Director, Alliance And Portfolio Management | Leadership |
Noelle Mullin | Associate Director, Discovery And Translational Medicine | Leadership |
Jon Wojciak | Senior Director, Preclinical Development | Leadership |
Shan Hwang | Head of Protein Sciences | Leadership |
Ryan Henrici | Senior Director of Translational Research | Leadership |
Steve Doberstein | Advisor | Board & advisors |
Jacob Gardner | Advisor | Board & advisors |
Pauline Jen Ryan | Advisor | Board & advisors |
Andrew Gordon Wilson | Advisor | Board & advisors |
Brian Kobilka | Advisor | Board & advisors |
Greg Landes | Advisor | Board & advisors |
Nigel Reuel | Advisor | Board & advisors |
Stanley Lapidus | Advisor | Board & advisors |
Mark Pegram | Advisor | Board & advisors |
31 more people are available in the full profile.
Complete people profiles for BigHat
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BigHat
BigHat has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BigHat Biosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Synthetic biology platform provided for diagnostic and therapeutic applications. | frugibio.com | Ames, United States | 1976 | Mar 2022 | •••• |
Complete acquisition details for BigHat
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of BigHat
4 dated milestones of BigHat across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BigHat is founded.
- Funding First funding round of $5.3M.
- Acquisition Acquires BigHat Biosciences.
- Funding Latest funding round, Series C, of $75.0M.
Competitors of BigHat
BigHat has 8 listed competitors in our database, 8 of them funded. They include argenx, MacroGenics, Owkin, Formation Bio and Alexion, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| owkin.com | 2016 | Paris, France | $321.1M | 47 | An agentic AI platform is developed for biomedical research insights. | |
| formation.bio | 2016 | New York, United States | $608.25M | – | AI-powered drug discovery platform for various diseases | |
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| zailaboratory.com | 2013 | Shanghai, China | $160M | – | Antibody-based therapies for cancers and inflammatory diseases are developed. | |
| absci.com | 2011 | Vancouver, United States | $227.56M | 256 | AI-based technology is used for recombinant protein production in therapeutics. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. |
Detailed competitors of BigHat
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BigHat
The website of BigHat (bighatbio.com) receives about 9.1K visits a month and ranks #2,715,263 among all websites worldwide, #3,675 in Biotechnology and Pharmaceuticals.
- Monthly visits9.1K
▲ 42.3% vs previous month
- Unique visitors2.4K
per month
- Global rank#2,715,263
among all websites
- Category rank#3,675
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.7
- Average visit3 min 06 sec
- DevicesDesktop 45% · Mobile 55%
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as BigHat (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bighat
Complete news archive for BigHat
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BigHat
BigHat was founded in 2019.
BigHat is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Mark DePristo is the current CEO of BigHat. They have also founded this company.
BigHat is a funded company, having raised a total of $223.41M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5.3M, raised on Dec 2019.
BigHat was founded in 2019 and is based in San Carlos, United States. Antibody therapies are provided by the company using machine learning and synthetic biology. An AI-enabled platform called Milliner is offered to design antibodies targeting intractable conditions, including chronic illnesses and life-threatening diseases. Operations focus on the biotechnology sector, with services aimed at therapeutic development for complex health challenges.
BigHat's top competitors include argenx, Owkin and Formation Bio.
BigHat offers Milliner Platform.
BigHat has made 1 acquisition, including BigHat Biosciences.
BigHat has 21 investors. Key investors include Bristol-Myers Squibb, Amgen Business Development, Quadrille Capital, Gaingels, and GRIDS Capital.